CA3024216C — Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
Assigned to Pfizer Inc · Expires 2021-03-30 · 5y expired
What this patent protects
The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-Rmethylamino)methyl] phenyl 1-1 ,3,4,5-tetrahydro-6H-azepino(5 ,4,3 -cd] indol-6-one having the following structural formula, and to processes for their preparation. (see above formula) Such polymorphic for…
USPTO Abstract
The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-Rmethylamino)methyl] phenyl 1-1 ,3,4,5-tetrahydro-6H-azepino(5 ,4,3 -cd] indol-6-one having the following structural formula, and to processes for their preparation. (see above formula) Such polymorphic forms can be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.